Nymox Pharmaceutical Corporation (NYMX): Price and Financial Metrics


Nymox Pharmaceutical Corporation (NYMX)

Today's Latest Price: $2.24 USD

0.32 (16.67%)

Updated Dec 4 4:00pm

Add NYMX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NYMX Stock Summary

  • With a price/sales ratio of 1,178.79, Nymox Pharmaceutical Corp has a higher such ratio than 99.42% of stocks in our set.
  • With a year-over-year growth in debt of -84.21%, Nymox Pharmaceutical Corp's debt growth rate surpasses merely 2.71% of about US stocks.
  • As for revenue growth, note that NYMX's revenue has grown -59.1% over the past 12 months; that beats the revenue growth of just 3.67% of US companies in our set.
  • Stocks that are quantitatively similar to NYMX, based on their financial statements, market capitalization, and price volatility, are CRNX, ARNA, MRTX, CBMG, and CVM.
  • Visit NYMX's SEC page to see the company's official filings. To visit the company's web site, go to www.nymox.com.

NYMX Stock Price Chart Interactive Chart >

Price chart for NYMX

NYMX Price/Volume Stats

Current price $2.24 52-week high $4.79
Prev. close $1.92 52-week low $1.66
Day low $1.92 Volume 202,600
Day high $2.25 Avg. volume 197,569
50-day MA $2.17 Dividend yield N/A
200-day MA $2.74 Market Cap 172.95M

Nymox Pharmaceutical Corporation (NYMX) Company Bio


Nymox Pharmaceutical Corporation engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company was founded in 1989 and is based in Nassau, The Bahamas.


NYMX Latest News Stream


Event/Time News Detail
Loading, please wait...

NYMX Latest Social Stream


Loading social stream, please wait...

View Full NYMX Social Stream

Latest NYMX News From Around the Web

Below are the latest news stories about Nymox Pharmaceutical Corp that investors may wish to consider to help them evaluate NYMX as an investment opportunity.

Nymox (+8%) on track to file fexapotide applications in ~four months

Thinly traded micro cap Nymox Pharmaceutical Corp. ([[NYMX]] +8.3%) perks up on almost double normal volume, albeit on turnover of only 264K shares, on the heels of its announcement that its lead fexapotide program in benign prostatic hyperplasia (enlarged prostate) is on track despite COVID-19 disruptions.It expects to file marketing...

Seeking Alpha | June 19, 2020

Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement

Nymox Pharmaceutical Corporation (NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of its regulatory documentation has proceeded very well, despite the inherent limitations of the business environment in 2020.

Yahoo | June 19, 2020

Hedge Funds Cautiously Watching Pharmaceutical Corporation (NYMX)

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. In this article, we look at what those funds think […]

Yahoo | June 5, 2020

If You Had Bought Nymox Pharmaceutical (NASDAQ:NYMX) Shares Five Years Ago You'd Have Made 91%

It hasn't been the best quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) shareholders, since the share price...

Yahoo | May 5, 2020

Nymox Announces Important New Patent Developments

HASBROUCK HEIGHTS, N.J., April 21, 2020 -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international.

Yahoo | April 21, 2020

Read More 'NYMX' Stories Here

NYMX Price Returns

1-mo 8.74%
3-mo -12.50%
6-mo -42.42%
1-year 20.43%
3-year -39.78%
5-year -34.69%
YTD 1.82%
2019 67.94%
2018 -60.30%
2017 23.60%
2016 -18.60%
2015 720.00%

Continue Researching NYMX

Here are a few links from around the web to help you further your research on Nymox Pharmaceutical Corp's stock as an investment opportunity:

Nymox Pharmaceutical Corp (NYMX) Stock Price | Nasdaq
Nymox Pharmaceutical Corp (NYMX) Stock Quote, History and News - Yahoo Finance
Nymox Pharmaceutical Corp (NYMX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9215 seconds.